A Randomized, Open-label, Multicenter Study of Epoetin Alfa Comparing Two Extended Dosing Regimens, Once-every-two-weeks and Once-every-four-weeks, With the Once-weekly Dosing Regimen for Maintenance Treatment in Anaemic Subjects With Chronic Kidney Disease
Latest Information Update: 19 May 2014
At a glance
- Drugs Epoetin alfa (Primary)
- Indications Anaemia
- Focus Registrational; Therapeutic Use
- Sponsors Janssen Research & Development
- 19 May 2014 New trial record
- 30 Apr 2009
- 01 Feb 2009